Pharm-Olan International

Pharm-Olam International is a global contract research organization (CRO) providing comprehensive clinical research services to the pharmaceutical, biotechnology, and medical device industries. Established in 1994, the company specializes in Phase I through Phase IV clinical trials, with deep expertise in oncology, infectious diseases, and rare diseases. Pharm-Olam is recognized for its extensive global reach, operating in over 60 countries with a focus on "global decentralization" to leverage local expertise. In 2022, the company was acquired by CATO SMS, which subsequently rebranded as Allucent, to create a unified provider focused on the needs of small and mid-sized biotech companies. The organization offers a wide range of services including clinical trial management, regulatory affairs, and biometrics.